Journal of Antimicrobial Chemotherapy, Vol 39, 35-43, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
JM Woodcock, JM Andrews, NP Brenwald, JP Ashby and R Wise
The in-vitro activity of faropenem, a novel oral penem, was studied in
comparison with other beta-lactam antimicrobials against 711 recent
clinical isolates including Gram-negative, Gram-positive and anaerobic
bacteria. MIC data showed that faropenem was active against most members of
the Enterobacteriaceae (MICs < or = 4 mg/L), with reduced activity
against Serratia spp. (MIC90 = 32 mg/L). In common with its comparators,
faropenem had weak activity against Pseudomonas aeruginosa and
Stenotrophomonas maltophilia (MIC > 128 mg/L). Faropenem was active
against staphylococci, although for MRSA MICs were raised (MIC90 = 2 mg/L)
compared with those for MSSA (MIC90 = 0.12 mg/L). Faropenem was also found
to be active against streptococci, Neisseria spp., Enterococcus faecalis
and beta-lactamase-producing and non-producing strains of Haemophilus
influenzae and Moraxella catarrhalis. Of the anaerobic bacteria studied,
faropenem was most active against peptostreptococci and Clostridium
perfringens (MIC90 < or = 1 mg/L) and Bacteroides fragilis (MIC90 = 4
mg/L). An increase in inoculum from 10(4) to 10(6) cfu raised faropenem
MICs for Morganella morganii from 0.06-1 mg/L to 2-4 mg/L and for MRSA from
0.25-2 mg/L to 8 mg/L (a similar increase was not observed for MSSA). The
MICs of faropenem were not affected by the presence of either 20% or 70%
(v/v) serum. MICs for faropenem to 11 well characterized beta-lactamase
producers were similar to those of non-producers. In hydrolysis studies,
faropenem was shown to be highly stable to a number of beta-lactamases,
including TEM- 1, SHV-1, the extended spectrum beta-lactamases, TEM-3 and
TEM-9, and the beta-lactamase produced by Staphylococcus aureus (NCTC
11561).
JOURNAL ARTICLE
The in-vitro activity of faropenem, a novel oral penem
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. P Gettig, C. W Crank, and A. H Philbrick Faropenem Medoxomil Ann. Pharmacother., January 1, 2008; 42(1): 80 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Wexler, D. Molitoris, S. St. John, A. Vu, E. K. Read, and S. M. Finegold In Vitro Activities of Faropenem against 579 Strains of Anaerobic Bacteria Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3669 - 3675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Boswell, J. P. Ashby, J. M. Andrews, and R. Wise Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem J. Antimicrob. Chemother., October 1, 2002; 50(4): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites J. Antimicrob. Chemother., September 1, 2002; 50(3): 411 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. von Eiff, S. Schepers, and G. Peters Comparative in vitro activity of faropenem against staphylococci J. Antimicrob. Chemother., August 1, 2002; 50(2): 277 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Milatovic, F.-J. Schmitz, J. Verhoef, and A. C. Fluit In vitro activity of faropenem against 5460 clinical bacterial isolates from Europe J. Antimicrob. Chemother., August 1, 2002; 50(2): 293 - 299. [Full Text] [PDF]
|
|
|
|
|
|
M. du Plessis, T. P. Capper, and K. P. Klugman In vitro activity of faropenem against respiratory pathogens J. Antimicrob. Chemother., March 1, 2002; 49(3): 575 - 577. [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, M. Boos, S. Mayer, J. Verhoef, D. Milatovic, and A. C. Fluit In vitro activity of faropenem and 20 other compounds against {beta}-lactamase-positive and -negative Moraxella catarrhalis and Haemophilus influenzae isolates and the effect of serum on faropenem MICs J. Antimicrob. Chemother., January 1, 2002; 49(1): 220 - 223. [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, M. Boos, S. Mayer, J. Verhoef, D. Milatovic, and A. C. Fluit In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2001; 48(1): 148 - 152. [Full Text] [PDF]
|
|
|
|
|
|
K. Sato, N. Sato, H. Shimizu, T. Tsutiya, H. Takahashi, S. Kakizaki, H. Takayama, H. Takagi, and M. Mori Faropenem enhances superoxide anion production by human neutrophils in vitro J. Antimicrob. Chemother., September 1, 1999; 44(3): 337 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Kelly, M. R. Jacobs, and P. C. Appelbaum Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae J. Antimicrob. Chemother., May 1, 1999; 43(5): 707 - 709. [Abstract] [Full Text] [PDF]
|
|